Skip to main content
Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer Cambridge, UK, 20th May 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, today announced that it has moved to the Bio-Innovation Centre at the Cambridge Science Park, following the appointment of 15 new staff to its scientific and management teams including, Dr. Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer. These new hires and facilities will aid Mogrify in building a scalable…
20 May 2019, Cambridge, UK: STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, today announced that it has raised an additional£14 million bringing the total Series A financing to £30 million. The financing includes funding from new investor, Seroba Life Sciences (“Seroba”). STORM’s existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group also participated in the fundraise. This extension follows the company’s rapid progress to date. It will enable STORM to advance its broad…
Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has reported record-breaking growth in its overseas turnover in the 12-months since it was recognised with one of the UK’s most prestigious awards, The Queen’s Awards for Enterprise. Since receiving the Queen’s Award for Enterprise, International Trade for Outstanding Short-Term Growth in overseas in April 2018, Boyds, which has its headquarters in Crewe, has also grown its team with four senior appointments and opened new offices in Dublin and at Alderley Park.…
Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals. The commercial agreement with Lonza follows the award of an Innovate UK grant to Synpromics announced on 23 April 2018. Lonza and Synpromics worked together to develop and test these innovative promoters in Lonza’s industry-leading GS Xceed® Expression System. The inducible promoters will be used by Lonza to enable efficient production of several types of biological drug and is part…
14 May 2019: Norwich Plant Bioscience Ltd (PBL) and Leaf Expression Systems Ltd (Leaf) are delighted to announce a further development in their relationship, with PBL granting Leaf the exclusive rights to sub-license the Hypertrans® transient expression system, the core technology underpinning Leaf’s biologics and vaccines contract development and manufacturing services business. Apart from rights previously granted to PBL’s pre-existing licensees, this effectively transfers to Leaf full control of the Hypertrans® technology and associated patented intellectual property. This extension of…
Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical and healthcare sectors, has introduced a cell based bioassay service to meet rising demand for potency assessments. Cell based bioassays are the primary tool for determining the biological activity of molecules, making the potency tests a critical part of drug product and drug substance quality control, product release and stability testing. Biopharma companies need to generate this information to have confidence in their drugs and comply with…
In support of its continuing growth plans, Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has appointed a new CMC regulatory affairs professional. Claire Scruton joins Boyds as Senior Manager of CMC Regulatory Affairs and will be based at the organisation’s Cambridge office. At Boyds, Claire will provide strategic regulatory CMC advice and operational support across a range of therapeutic areas and development stages for ATMPs, biologics and new chemical entities. A CMC regulatory affairs professional, Claire…
Cell encapsulation for transport of cells and tissues at room temperature Cambridge, UK and Newcastle, UK, 9th May 2019 / Sciad Newswire / Atelerix, creator of an innovative cell encapsulation technology, today announces it has closed a second round of funding of £700,000 to accelerate development of its cell transport products to market. Atelerix’s products are used for the storage and transport of human cells and tissues at room temperature, removing the need for cryopreservation and the potential for cell degradation or damage. Atelerix sells its products and services to customers in the…
To support their ambitious growth plans, Dundee-based resourcing group Entrust Resource Solutions have acquired a second company, SCI Search and Selection, increasing their portfolio to three consultancies. The specialist life sciences and healthcare resourcing group now comprise three like-minded consultancies located in key locations across the UK: Entrust People, Horton International UK and SCI Search and Selection. With the addition of a North West location, the group is closer to Manchester’s thriving life sciences industry, with world leading research and development assets, the largest…
Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting insulin product candidate, AT247. Arecor’s AT247 is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. The novel formulation of AT247 is designed to deliver an acceleration of insulin…